… by The Michael J. Fox Foundation (MJFF), Austrian biotech company AFFiRiS brought the first therapy targeting the Parkinson’s protein alpha-synuclein into clinical trials. Its PD01 vaccine prompts the body to … and follow-up trials of boost vaccines. Early trials  showed positive results  around safety and alpha-synuclein …

… Study Rationale:     The symptoms and course of Parkinson’s disease (PD) show remarkable variation from one person to another, … to these variations. By considering the effect of a combination of gene variants, it is possible to generate … Analysis of Patient-Reported Outcomes from Fox Insight …

… that I will be able to improve my patients' clinical outcomes because of this course." As a complement to this program, MJFF, also in partnership with …

… Matt Farrer , PhD, and colleagues had linked a new gene to Parkinson’s disease (PD).  Dr. Farrer’s team made the … family – six brothers all developed late-onset PD.  Their commitment to research has spanned the past 28 years. We … with Drs. Farrer and Fiske. MJFF: Tell us more about how this study came about. Dr. Farrer: In 2012, about 70 …

… of Parkinson’s disease (PD) and turning that knowledge into better treatments is a complex undertaking. In this episode of the award-winning … scientists at The Michael J. Fox Foundation (MJFF) discuss how they are tackling this problem from every angle. Whether …

… focused her research on genetic conditions among the Amish community, ultimately leading to discoveries on the genetics of mental illness in a … control what your assets will go toward. Janice’s story shows us all that when we plan for the future, we can truly …